ALERTS & COVID-19 UPDATES Learn more: COVID-19 Resources; COVID-19 Testing; Vaccine Info; Visitor Policy; Support Us

[LCID Study Number: 2017-081CIRB]

S1616: A Phase II Randomized Study of Nivolumab (NSC-748726) with Ipilimumab (NSC-732442) OR Ipilimumab Alone in Advanced Melanoma Patients Refractory to an Anti-PD-1 or Anti-PD-L1 Agent

The purpose of this study is to compare the effects of combining two drugs, ipilimumab and nivolumab, in treatment for patients with advanced melanoma. Both of these drugs are FDA approved for use individually on several cancers, however use together is not approved, or investigational.

Primary Contact Email: [email protected]

Primary Contact Phone: 781-744-3055